Introducing your Roche Haematology Clinical Educators

Meet Your Roche Haematology Clinical Educators

POLIVY® (polatuzumab vedotin) Prescribing Information (UK)

COLUMVI®▼ (glofitamab) Prescribing Information (UK)

Our Clinical Educators bring extensive nursing experience and are here to support you in enhancing the care you provide to your patients.

They can support you and your team by:

Supporting Patient Care: Providing tailored education on Diffuse Large B-Cell Lymphoma (DLBCL) and Roche haematology products to build your confidence in managing therapies.
Supporting Patient Safety: Training on recognising and managing adverse events associated with Roche haematology products.
Strengthening Clinical Practice: Facilitating nurse networking and best-practice sharing to drive better patient outcomes.
Fostering Collaborative Care: Supporting NHS meetings and multidisciplinary teams to enable system-wide improvements in patient care.

Sharon Steadman, RGN

sharon.steadman@roche.com

Mobile: +44 (0)7584 118230

Sharon completed her nurse training in 1999 at Southampton University Hospital. Since then, she has built a diverse nursing career with experience in Orthopaedics, Medicine, and Respiratory care. In 2005, she specialised as a SACT nurse, supporting patients receiving Oncology and Haematology treatments. Her passion for cancer care led her to become an Oncology Clinical Nurse Specialist, further deepening her expertise in the field.

Region: South West England, Northern England (North East, Yorkshire), Wales, Scotland, Northern Ireland

Deborah Whitney

deborah_ann.whitney@roche.com

Mobile: +44 (0)7866 673209

Deb completed her nurse training at the Royal London Hospital in 1990. Her experience encompasses diverse specialities such as HIV/ Hepatitis C, Trauma and Orthopaedics, general surgery, and ward management. Complementing her clinical expertise, Deb also has a significant background in clinical research, having contributed to this field within both the NHS and the pharmaceutical industry.

Region: Southern England (South East & South West), East of England, Midlands, North West England

▼ Columvi (glofitamab) is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Reporting suspected adverse reactions after authorisation of medicinal products is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events for both Columvi (glofitamab) and Polivy (polatuzumab vedotin) should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. Adverse reactions should be reported by brand name and batch number.